Acadian Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$142K Buy
+23,484
New +$167K ﹤0.01% 1673
2024
Q4
Sell
-1,761
Closed -$28K 2079
2024
Q3
$28K Buy
+1,761
New +$27.5K ﹤0.01% 1929
2023
Q2
Sell
-50,308
Closed -$2.1M 1885
2023
Q1
$2.1M Sell
50,308
-5,343
-10% -$251K 0.01% 697
2022
Q4
$1.89M Buy
55,651
+11,110
+25% +$473K 0.01% 692
2022
Q3
$2.19M Buy
44,541
+8,264
+23% +$454K 0.01% 613
2022
Q2
$1.43M Buy
36,277
+30,213
+498% +$896K 0.01% 729
2022
Q1
$222K Sell
6,064
-13,030
-68% -$815K ﹤0.01% 1189
2021
Q4
$1.87M Sell
19,094
-8,207
-30% -$883K 0.01% 674
2021
Q3
$3.4M Buy
27,301
+5,703
+26% +$689K 0.01% 542
2021
Q2
$2.71M Buy
21,598
+9,330
+76% +$1.11M 0.01% 627
2021
Q1
$1.67M Buy
+12,268
New +$1.52M 0.01% 790
2020
Q3
Sell
-307
Closed -$26K 2325
2020
Q2
$26K Buy
+307
New +$27.8K ﹤0.01% 2081
2019
Q3
Sell
-584
Closed -$31K 1983
2019
Q2
$31K Buy
+584
New +$39.8K ﹤0.01% 1551

Other funds holding RNAC

Acadian Asset Management's RNAC Position: Q1 2026 in Review

Acadian Asset Management opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 23,484 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #1673 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in RNAC as recently as Q3 2024.

Acadian Asset Management first reported a position in RNAC in Q2 2019 and has held it in 13 quarters since. The position peaked at $3.4M in Q3 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Acadian Asset Management held 23,484 shares of Cartesian Therapeutics worth $142K as of Q1 2026.
  • Cartesian Therapeutics was a new Acadian Asset Management position in Q1 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1673 holding.
  • Acadian Asset Management first reported a position in Cartesian Therapeutics in Q2 2019 and has held it in 13 quarters since.
  • Acadian Asset Management's Cartesian Therapeutics position peaked at $3.4M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.